As a next step in a series of corporate governance modifications,
McKesson Corporation (NYSE: MCK) today announced that its Board of
Directors has elected N. Anthony Coles, M.D., as a new independent
director, effective April 29, 2014. In connection with Dr. Coles’
election, the size of the Board of Directors was increased from nine to
ten members, nine of whom are independent.
N. Anthony Coles, M.D. (Photo: Business Wire)
“With over 20 years of experience in the biopharmaceuticals and
pharmaceutical industries, including several public company leadership
positions, Tony will provide unique perspectives that will further
diversify the expertise of our Board,” said John H. Hammergren, chairman
and chief executive officer, McKesson Corporation. “We are committed to
maintaining the best possible leadership team to continue guiding our
strong financial performance. The addition of Tony to our Board
represents a continuation of initiatives already under way to address
shareholder feedback and maintain industry-leading governance practices.”
The Board has appointed Dr. Coles as a member of its Compensation
Committee and its Finance Committee. Dr. Coles’ term as a director will
expire at the Company’s 2014 Annual Meeting of Stockholders unless he is
renominated as a director, and elected by stockholders at the annual
meeting in accordance with McKesson’s majority voting standard.
N. Anthony Coles, M.D.
Dr. Coles, 53, was President, Chief Executive Officer and Chairman of
the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company,
from 2012 until 2013, having served as its President and Chief Executive
Officer, and a member of its board of directors, from 2008 until 2012.
From 2005 to 2008, Dr. Coles served as an executive and a director of
NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”).
Dr. Coles began his tenure at NPS as President and Chief Operating
Officer and ended his tenure there as President and Chief Executive
Officer. Prior to 2005, Dr. Coles served in various leadership positions
in the biopharmaceutical and pharmaceutical industries, including at
Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex
Pharmaceuticals Incorporated.
About McKesson Corporation
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a
healthcare services and information technology company dedicated to
making the business of healthcare run better. McKesson partners with
payers, hospitals, physician offices, pharmacies, pharmaceutical
companies and others across the spectrum of care to build healthier
organizations that deliver better care to patients in every setting.
McKesson helps its customers improve their financial, operational, and
clinical performance with solutions that include pharmaceutical and
medical-surgical supply management, healthcare information technology,
and business and clinical services. For more information, visit www.mckesson.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140305005569/en/
Copyright Business Wire 2014